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Objective: To establish if palpable breast masses with
benign greyscale ultrasound features that are soft on
shear-wave elastography (SWE) (mean stiffness ,50kPa)
have a low enough likelihood of malignancy to negate the
need for biopsy or follow-up.
Methods: The study group comprised 694 lesions in 682
females (age range 17–95 years, mean age 56 years)
presenting consecutively to our institution with palpable
lesions corresponding to discrete masses at ultrasound.
All underwent ultrasound, SWE and needle core biopsy.
Static greyscale images were retrospectively assigned
Breast Imaging Reporting and Data System (BI-RADS)
scores by two readers blinded to the SWE and pathology
findings, but aware of the patient’s age. A mean stiffness
of 50kPa was used as the SWE cut-off for calling a lesion
soft or stiff. Histological findings were used to establish
ground truth.
Results: No cancer had benign characteristics on both
modalities. 466 (99.8%) of the 467 cancers were classi-
fied BI-RADS 4a or above. The one malignant lesion
classified as BI-RADS 3 was stiff on SWE. 446 (96%) of
the 467 malignancies were stiff on SWE. No cancer in
females under 40 years had benign SWE features. 74
(32.6%) of the 227 benign lesions were BI-RADS 3 and
soft on SWE; so, biopsy could potentially have been
avoided in this group.
Conclusion: Lesions which appear benign on greyscale
ultrasound and SWE do not require percutaneous biopsy or
short-term follow-up, particularly in females under 40 years.
Advances in knowledge: None of the cancers had benign
characteristics on both greyscale ultrasound and SWE,
and 32% of benign lesionswere BI-RADS 3 and soft on SWE;
lesions that are benign on both ultrasound and SWE may
not require percutaneous biopsy or short-term follow-up.
INTRODUCTION
Shear-wave elastography (SWE) allows quantitative and
reproducible measurements of lesion stiffness in kilopascals
and can be performed quickly during routine breast ul-
trasound examinations. It has been shown to yield accurate
information with regard to benign/malignant differentia-
tion of solid breast masses.1–3 SWE allows measurement of
the propagation speed of shear waves within the tissue, to
locally quantify its stiffness in kilopascals or metre per
second. A variety of quantitative measures can be obtained
with SWE, including the mean, maximum and “standard
deviation” from a user-deﬁned region of interest (ROI).
Qualitative assessments have also been found to be useful
(shape at SWE, pattern of stiffness and heterogeneity of
stiffness).1–5 Several large studies have shown that the ad-
dition of SWE to greyscale ultrasound improves the per-
formance of ultrasound in differentiating benign from
malignant breast masses.1,3,6 Notably, the combination of
benign SWE and greyscale ultrasound ﬁndings has been
shown to be highly speciﬁc, and malignancy is extremely
unlikely, with a negative-predictive value for the combina-
tion of 100%.6 The SWE parameter of mean stiffness is
highly accurate in differentiating between benign and ma-
lignant solid breast masses and has performance parameters
at least as good as the Breast Imaging Reporting and Data
System (BI-RADS) evaluation of greyscale images.6 Cancers
classiﬁed as benign by quantitative SWE are uncommon and
are more often small (#10mm), low grade or pure ductal
carcinoma in situ (DCIS).7 Since such tumours are more
frequently detected at screening, SWE has been found to
have superior performance in females who are symptomatic
compared with females with screen-detected abnormalities
(SWE sensitivity has been found to be 99% in symptomatic
patient and 87% in screening patient).7
Because of the very low incidence of malignancy in young
females, there has been a tendency not to biopsy or even follow-
up females under 25 years with solid breast masses with benign
features on greyscale ultrasound.8 This has been possible because
of the accuracy of modern greyscale ultrasound in differentiating
benign from malignant breast masses.9–12 Indeed, in some units
in the UK, this arbitrary age cut-off for biopsy or follow-up has
been safely increased to 30 years.13
We hypothesize that palpable breast masses having both benign
greyscale (BI-RADS Category 3)14 and SWE features have a very
low chance of being malignant and biopsy or follow-up may not
be required. We have therefore reviewed a prospectively collected
consecutive series of palpable breast masses, visible on ultra-
sound, with both SWE and BI-RADS classiﬁcation, to assess the
malignancy rate in females with masses that have benign grey-
scale and SWE features.
METHODS AND MATERIALS
SWE has been part of the routine breast ultrasound examination
of solid breast masses at our institution since November 2009. In
accordance with the applicable National Research Ethics Service
guidance, ethical approval for the study was not required (Na-
tional Research Ethics Service, 2008). However, written in-
formed consent to use images was obtained, according to
routine practice in our institution.
All consecutive patients with palpable mass were scanned using
the Aixplorer ultrasound system® (SuperSonic Imagine, Aix en
Provence, France) between 29 December 2010 and 4 April
2014. Those patients with discrete masses on greyscale ultra-
sound, subjected to core needle biopsy and/or surgical biopsy
according to standard clinical protocols were included in
this study.
32 females who did not have a discrete lump at ultrasound
imaging were excluded. Images from a further six patients were
not available, and these were excluded. Thus, the ﬁnal cohort for
this study included 682 patients with 694 lesions.
All females were scanned and biopsied with ultrasound guidance
by one of ﬁve breast radiologists (AE, SV, KT, DM, GE) or an
advanced radiography practitioner trained to perform and in-
terpret breast ultrasound. These practitioners had between 7 and
22 years’ experience in breast ultrasound and had a minimum of
3 months’ experience of performing SWE of solid breast lesions.
Greyscale and elastography images were obtained during the
standard ultrasound appointment. Acquisition of the elas-
tography images added 1–2min to the examination time. The
elastography colour map ﬁndings were taken into account in the
diagnostic management of the patients, but the quantitative
measurements were produced and analyzed post hoc to minimize
impact on workﬂow. Extracting the quantitative data at the end
of the clinic took 1–2min for each lesion. The ROI utilized in all
cases was 2mm in diameter. As the ROI is moved by the op-
erator, the ﬁgures change in real time so that the stiffest ROI can
be identiﬁed. A cut-off value for mean elasticity of the ROI of
50 kPa was used for benign/malignant differentiation, as this
level has been validated in previous studies.2,6,15
Static greyscale images underwent retrospective standard BI-RADS
classiﬁcation by a breast radiologist and a breast radiology trainee,
both blinded to the elastography and pathology ﬁndings but
aware of the patient’s age (Category 3: probably benign, Category 4a:
low suspicion, Category 4b: intermediate suspicion, Category 4c:
moderate suspicion and Category 5: highly suggestive of malig-
nancy).16 BI-RADS Categories 1–3 were taken as negative, since
the American College of Radiology guidelines state that such
lesions can be managed without immediate biopsy. BI-RADS scores
of 4 or 5 were taken as positive.17 Differences between the readers
were resolved by consensus.
Core biopsies were performed using a 14-g automated gun
under ultrasound guidance. When repeat biopsies, vacuum-
assisted biopsies/removals or surgery were performed, the ﬁnal
histological diagnosis was used for analysis. The proportion of
malignancies in lesions with BI-RADS 3 classiﬁcation and av-
erage mean stiffness ,50 kPa was obtained.
Statistical analyses
For the purposes of this analysis, continuous variables were
dichotomized (for example, lesion size was dichotomized into .
or ,10mm). The signiﬁcance of differences in categorical var-
iables between groups was assessed using x2 and Fisher’s exact
tests, and p-values of #0.05 were taken to indicate statistical
signiﬁcance. Analyses were performed using IBM SPSS® v. 21
(IBM, Portsmouth, UK).
RESULTS
694 lesions in 682 patients (age range 17–95 years, mean age
56 years) were included in the study. 227 (32.7%) lesions were
benign (age range 19–91 years, mean age 42 years) and 467
(67.3%) lesions were malignant (age range 24–95 years, mean
age 63 years).
The histological characteristics of the benign lesion are shown in
Table 1; the commonest benign lesion was ﬁbroadenoma. Of the
467 malignant lesions, 459 (98.2%) lesions were invasive carci-
noma. The commonest invasive cancer was grade 3 ductal car-
cinoma of no special type, which was .15mm. There were
4 (0.8%) DCIS masses, 1 (0.2%) metastasis from melanoma,
2 (0.4%) lymphomas and 1 (0.2%) plasmacytoma. The charac-
teristics of the lesions according to age are shown in Table 2. The
Table 1. Benign lesion characteristics
Characteristics Number of lesions (%)
Fibroadenoma 141 (62.1)
Fibrocystic change 26 (11.5)
Inﬂammation 10 (4.4)
Papilloma 8 (3.5)
Lobular carcinoma in situ 4 (1.8)
Fat necrosis 9 (3.9)
Others 29 (12.8)
Total 227 (100)
BJR Giannotti et al
2 of 7 birpublications.org/bjr Br J Radiol;89:20150865
mean ultrasound size of lesions in the study was 19.4 mm
(benign lesions, 17 mm; malignant lesions, 21 mm).
223 (32.1%) of the 694 lesions were assigned different
BI-RADS scores by the two readers; 13 (1.8%) lesions were
classiﬁed as BI-RADS 3 by one reader but as BI-RADs 4a by the
other reader. There were no cases where a lesion was classiﬁed
as BI-RADS 3 by one reader and BI-RADS 4b, 4c or 5 by
the other.
466 (99.8%) of the 467 cancers were classiﬁed BI-RADS 4a or
above; the BI-RADS scores of the cancers are shown in Table 3.
Only one cancer was classiﬁed as BI-RADS 3; the one (0.2%)
malignant lesion classiﬁed as BI-RADS 3 by both readers was
a 12-mm lesion in a 72-year-old patient, which was stiff on SWE
(mean stiffness 119 kPa) and occult on mammography (Figures
1 and 2). It was a grade 2 invasive ductal carcinoma of no special
type measuring 32mm at ﬁnal pathology.
21 (4.5%) of the 467 cancers were soft on SWE (mean stiffness
of ,50 kPa). 10 (47.6%) of these were ,10mm on greyscale
ultrasound size and 15 (71.4%) cancers were ,15mm. 2 (9.5%)
cancers were pure DCIS, 2 (9.5%) cancers were lymphoma and
1 (4.8%) cancer was a plasmacytoma. The remaining 16 (76.2%)
cancers were invasive cancers (age range 40–68 years, mean age
60 years), with histological characteristics shown in Table 4.
Thus, 3.5% of invasive breast cancers were classiﬁed as benign
on SWE.
No malignancies in females aged under 40 years had benign
shear-wave values. Of the 21 soft malignancies, 6 (28.6%)
malignancies occurred in females aged 40–50 years, 5 (23.8%)
malignancies in females aged 50–60 years, 4 (19.0%) malig-
nancies between 60–70 years and 6 (28.6%) malignancies over
70 years.
Benign lesions
Of the 227 benign lesions, 83 (36.6%) lesions were classiﬁed
as BI-RADS 3 on greyscale ultrasound, 79 (34.8%) lesions as
BI-RADS 4a, 46 (20.3%) lesions as BI-RADS 4b, 12 (5.3%) lesions
as BI-RADS 4c and 7 (3%) lesions as BI-RADS 5. 149 (65.6%)
lesions were soft on SWE and 78 (34.4%) lesions were stiff. 73
(32.2%) lesions were correctly classiﬁed as benign by both SWE
and greyscale ultrasound.
Of the lesions classiﬁed as BI-RADS 4a on greyscale that were
soft on SWE, 54 (91.5%) lesions were benign; only 5 (8.5%)
lesions were cancers.
The positive-predictive value of BI-RADS classiﬁcation was
18.5% for BI-RADS 4a, 61% for BI-RADS 4b, 92.8% for
BI-RADS 4c and 96.9% for BI-RADS 5. The negative-predictive
value of the BI-RADS classiﬁcation was 98.8% for BI-RADS 3.
Patients aged under 40 years
Of the 131 lesions in patients under 40 years, 107 (81.7%)
lesions were benign and 24 (18.3%) lesions were malignant.
All 24 cancers were stiff on SWE; and none were classiﬁed as
BI-RADS 3 on greyscale ultrasound. 3 (12.5%) cancers were
classiﬁed as BI-RADS 4a, 10 (41.7%) cancers as BI-RADS 4c and
11 (45.8%) cancers as BI-RADS 5. Of the 107 benign lesions,
43 (40.2%) lesions were correctly classiﬁed as benign by both
SWE and BI-RADS.
Patients aged under 50 years
Of the 314 lesions in patients aged under 50 years, 180 (57.3%)
lesions were benign and 134 (42.7%) lesions were malignant. Of
the 134 cancers, 6 (4.5%) cancers were soft on SWE; none were
BI-RADS 3 on greyscale ultrasound. 6 (4.5%) cancers were
classiﬁed as BI-RADS 4a, 16 (11.9%) cancers as BI-RADS 4b,
51 (38.1%) cancers as BI-RADS 4c and 61 (45.5%) cancers as
BI-RADS 5.
Of the 180 benign lesions, 126 (70%) lesions were soft on SWE
and 67 (37.2%) lesions were correctly classiﬁed as benign by
SWE and BI-RADS.
Table 2. Number and characteristics of lesions according to age
Patient age (years) Number of patients Number of cancers (%)
,30 46 3 (6.5)
30–39.99 87 21 (24.1)
40–49.99 183 110 (60.1)
50–59.99 98 74 (75.5)
60–69.99 95 85 (89.5)
70–79.99 91 87 (95.6)
$80 94 87 (92.5)
Table 3. Malignant lesions Breast Imaging Reporting and Data
System (BI-RADS) classifications
BI-RADS classification Number of lesions (%)
BI-RADS 3 1 (0.2)
BI-RADS 4a 18 (3.9)
BI-RADS 4b 72 (15.4)
BI-RADS 4c 157 (33.6)
BI-RADS 5 219 (46.9)
Full paper: SWE and ultrasound of palpable probably benign masses: is biopsy always required? BJR
3 of 7 birpublications.org/bjr Br J Radiol;89:20150865
DISCUSSION
We have found that the combination of greyscale ultrasound and
SWE is very sensitive for the diagnosis of malignancy in females
with symptomatic breast masses. None of the 467 palpable
cancers had benign characteristics on both ultrasound
modalities.
UK breast radiologists use the Royal College of Radiologist ﬁve-
point classiﬁcation system which differs from BI-RADS, as it
does not specify the percentage of likelihood of malignancy as-
sociated with each category. So, whereas BI-RADS 3 represents
probably benign and short-term follow-up is required, UK Royal
College of Radiologist 3 represents probably benign/
indeterminate and further investigations are warranted.18 In
the UK, it is usual practice for a benign diagnosis to be made on
the basis of clinical and ultrasound ﬁndings without immediate
biopsy in young females under 25 years.8–10 Conversely, it is
standard policy in most breast units to perform percutaneous
biopsy (or short-term follow-up) on solid benign masses pre-
senting over the age of 25 years.8 Some units have safely changed
their policy and have extended the age below which they do not
perform biopsy to 30 years through strict adherence to BI-RADS
criteria for a benign solid breast mass, without any instances of
missed breast cancers.13
In our study, 33.4% of cases were assigned different BI-RADS
scores by the two readers, and these differences were resolved by
consensus. There are few studies evaluating the observer
agreement of the BI-RADS lexicon for ultrasound, despite its
introduction in 2003. These studies show a higher level of
intraobserver agreement than interobserver agreement. In these
studies, the intraobserver agreement varied between substantial
and almost perfect, while the interobserver agreement for
sonographic descriptors varied between fair and substantial.
The highest agreement was found for mass orientation and
the lowest for margin assessment, with an interobserver
agreement for BI-RADS ﬁnal category that was moderate.
The low levels are owing to subcategorizing of BI-RADS 4
into 4a, 4b and 4c; and these results are similar to our study.19
The boundary between BI-RADS 3 and 4a and above is im-
portant because management may change as a consequence.
Disparity between the two assessors in this study crossed this
boundary in only ,2% of cases. This suggests that the BI-
RADS assessment used in this study should be highly
reproducible.
The accuracy of SWE in benign and malignant differentiation,
when added to greyscale ultrasound and clinical ﬁndings, is
likely to lead to an increase in the number of benign lesions
that can be accepted as such, without requiring percutaneous
biopsy.1,6,20 The ﬁndings of this study suggest that lesions
which appear benign on both greyscale ultrasound and SWE do
not require percutaneous biopsy or short-term follow-up. In
this study, application of these criteria could have obviated the
need for biopsy in 32.6% of benign lesions. Adding SWE
ﬁndings to BI-RADS features for Category 3 and 4a lesions has
been shown to improve speciﬁcity, without loss of sensitivity.1
These authors also found that stiffness on SWE examination
helped identify the few malignancies that would otherwise have
been assessed as BI-RADS Category 3.1
Studies of cancers misclassiﬁed as benign by greyscale ultra-
sound and SWE suggest that greyscale ultrasound and SWE may
be complimentary modalities. Greyscale ultrasound tends to
Figure 1. Greyscale ultrasound image of a solid lesion classified as Breast Imaging Reporting and Data System 3 by both readers.
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misclassify high-grade, triple-negative breast cancers as benign,
as such cancers can have well-deﬁned margins and often lack the
distal acoustic shadowing seen in lower grade luminal
cancers.20–22 By contrast, SWE tends to misclassify low-grade
cancers, particularly tubular cancers, as benign.7 SWE has the
additional advantage of being equally sensitive for the detection
of lobular cancers and ductal cancers, in contrast to greyscale
ultrasound.23 These data suggest that the rate of cancers having
negative ﬁndings on both greyscale ultrasound and SWE will be
lower than the false-negative rates of each modality alone. The
practical clinical implications of our ﬁndings are substantial, for
the patient and the wider National Health Service. Discharge of
patients from symptomatic clinics with breast masses that have
benign greyscale ultrasound and SWE characteristics would be
beneﬁcial, as they would not undergo the trauma of core biopsy
nor the anxiety of waiting for results. It would greatly beneﬁt
underresourced breast radiologists and ultrasound practitioners,
who would not have to perform as many biopsies, and it would
decrease the burden on histopathology services and shorten
multidisciplinary breast team meetings.
The sensitivity of the BI-RADS classiﬁcation of greyscale images
in this study is particularly high. A number of factors may be
responsible for this. Firstly, this study included only symptom-
atic masses; small screen-detected lesions which are more
difﬁcult to characterize were not included. Secondly, the age of
the patient was known; so, this may have inﬂuenced the readers.
Thirdly, the classiﬁcation was performed by two readers and
a consensus reached. This would exclude any obvious errors
from being made.
There are a number of limitations to this study. Although the
study contains a large number of cancers, it was performed at
a single centre with a special interest in SWE. It is not known
whether the results of this study are applicable to other centres.
SWE is not a difﬁcult technique to learn and it has been found
to be highly reproducible; so, it is likely that similar results
would be obtained in other centres. However, SWE is available
from a number of manufacturers and there are technical dif-
ferences between the systems. Therefore, results from one SWE
system may not be applicable to systems from other manu-
facturers and it would be essential to carry out similar studies
using other manufacturer equipment.
If the results can be replicated by other investigators, then the
use of SWE imaging in combination with greyscale ultrasound
could greatly simplify the management of BI-RADS Category
3 benign breast masses, by obviating the need for biopsy or follow-
up, especially in females under 40 years, in whom there are no
soft cancers. SWE is available as an add on to an increasing
Figure 2. Shear-wave elastography (SWE) image showing high peritumoral stiffness (mean stiffness 119 kPa). Percutaneous core
biopsy and subsequent surgery confirmed the presence of a grade 2 invasive ductal carcinoma of no special type.
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number of ultrasound machines; so, the cost of implementing
SWE is small. The introduction of a policy of not biopsying
lesions with both benign greyscale and SWE characteristics is
therefore likely to lead to signiﬁcant cost savings for healthcare
providers as detailed above, as well as provide a quicker yet safe
service to patients. This study has not included ﬁndings of clinical
examination; physical examination ﬁndings in clinical practice
would provide a further safeguard against the discharge of females
from the clinic without biopsy, in whom there is a breast cancer.
CONCLUSION
This study has shown that the combination of greyscale ul-
trasound and SWE is very sensitive for the diagnosis of ma-
lignancy in females with symptomatic breast lumps. Our
ﬁndings suggest that lesions which appear benign on greyscale
ultrasound that are soft on SWE do not require percutaneous
biopsy or short-term follow-up. The introduction of a policy of
not biopsying benign lesions with benign greyscale and soft
SWE characteristics would beneﬁt patients, clinicians and
healthcare providers alike. Nonetheless, further studies with
larger populations, using equipment from different manu-
facturers, are needed to validate our results.
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